Neuralstem (NYSEMKT:CUR) could be on the brink of something quite remarkable with their neurogenerative drug NSI-189. My last article covered what I thought to be an early valuation of what NSI-566, Neuralstem's ALS intraspinal stem cell therapy could be worth. In this article, I will attempt to do the same with NSI-189 for MDD.
MDD (Major Depressive Disorder)
MDD is characterized by a combination of symptoms that interfere with a person's ability to work, sleep, study, eat, and enjoy once-pleasurable activities. It is disabling and prevents a person from functioning normally. An episode of major depressive disorder may occur only once in a person's lifetime, but more often it occurs chronically throughout a person's life. Major depressive disorder...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|